The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and pharmacological strategies without systematic methodology
PubMed 16353941 · doi:10.1208/aapsj070364
What was done
This narrative review summarizes the biological mechanisms of the endocannabinoid system—including CB1 receptors on nerve terminals, CB2 receptors on immune cells, and endogenous ligands—and evaluates pharmacological strategies to modulate endocannabinoid levels or receptor activity across central and peripheral disorders.
What was found
The abstract reports no empirical data or quantitative effect sizes. It details several proposed therapeutic strategies: using brain-penetrant or peripherally restricted CB1/CB2 agonists or antagonists; local or intrathecal agonist administration; utilizing partial rather than full agonists; co-administering cannabinoid agonists with noncannabinoids like opioids; inhibiting or activating endocannabinoid synthesis, uptake, or enzymatic degradation; using CB1 allosteric modulators; and employing CB2 inverse agonists.
Why it matters
It outlines a structural classification of pharmacological approaches for drug discovery targeting the endocannabinoid system, noting that endogenous upregulation can be either protective or harmful depending on the underlying pathology.
Limits
As a broad narrative review, it presents no original data, sample sizes, clinical trial results, or systematic review methodology in the abstract. Clinical efficacy, safety, and specific patient population outcomes are not measured.
Cited by
- supports The human endocannabinoid receptor system is distributed throughout both the brain and the peripheral body.